KABRA DRUGS LTD.

Kabra Drugs Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting to consider these financial results will be communicated separately.

Kabra Drugs Limited has received a Letter of Intent (LOI) from the Government of Chhattisgarh for a ₹200 Crore pharmaceutical manufacturing facility at Nava Raipur Pharma Park. The project aims to expand the company's manufacturing footprint, enhance operational capabilities, and increase production capacity. The facility is expected to generate approximately 250 direct and indirect employment opportunities. This strategic investment aligns with Kabra Drugs' long-term expansion strategy and is subject to definitive agreements and necessary approvals. The company anticipates benefiting from state government policies and incentives.

Kabra Drugs Ltd has received a Letter of Intent (LOI) from the Government of Chhattisgarh to establish a pharmaceutical manufacturing facility at Nava Raipur Pharma Park. The proposed project involves an investment of approximately ₹200 Crore and is expected to significantly enhance the company's manufacturing capabilities and support its long-term growth strategy. The facility is anticipated to create around 250 direct and indirect employment opportunities. The investment is contingent upon the execution of definitive agreements and obtaining necessary approvals and sanctions.

Kabra Drugs Ltd has received a Letter of Intent (LOI) from the Government of Chhattisgarh to establish a pharmaceutical manufacturing facility at Nava Raipur Pharma Park. The project involves an investment of approximately ₹200 Crore and is expected to significantly enhance the company's manufacturing capabilities and support long-term growth. The facility is projected to create around 250 direct and indirect employment opportunities. The investment is contingent upon the execution of definitive agreements and obtaining necessary approvals and incentives.

Kabra Drugs Ltd reported exceptional FY26 financial results, with total income reaching ₹93.23 crore, a 14,463.06% YoY increase. The company's EBITDA and PAT turned positive. In Q4 FY26, total income rose to ₹35.52 crore, a 5,448.13% YoY growth. EBITDA grew by 264.83% YoY to ₹1.45 crore, and PAT increased by 170.15% YoY to ₹1.06 crore. The company is expanding its pharmaceutical manufacturing and marketing, exploring AI-led defence technologies, and establishing an AI & Defence Technology R&D facility in Chennai.

Kabra Drugs Ltd's board meeting on May 29, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The company reported a total income of ₹3,551.91 lakhs for the quarter ended March 31, 2026, and ₹9,323.27 lakhs for the financial year ended March 31, 2026. The net loss after tax for the year stood at ₹108.56 lakhs. The board confirmed that Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable as the company has not issued shares via public, right, or preferential issues.

Kabra Drugs Ltd. has announced that Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company for the quarter ended March 31, 2026. This is because the company has not issued any shares through public issue, rights issue, or preferential issue during the specified quarter. Mr. Nanjappan Aravind, Managing Director of Kabra Drugs Limited, has certified the same.

Kabra Drugs Ltd has announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the financial statements on May 29, 2026. Revenue from Operations stood at ₹9,274 lakhs for the financial year ended March 31, 2026. Net Profit after Tax is ₹495.98 lakhs. The company has restated comparative quarterly figures due to the impact of Ind AS 116.

Kabra Drugs Ltd. approved the audited financial results for the quarter and financial year ended March 31, 2026. The company's revenue from operations for the year stood at ₹9,274.00 lakhs. Net profit after tax for the year was reported as ₹495.98 lakhs. The Board meeting, which commenced at 05:00 p.m. (IST) and concluded at 06:30 p.m. (IST), also confirmed that Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company.

Kabra Drugs Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the unaudited financial results for the quarter ended March 31, 2026. The meeting will also address any other agenda items with the chair's permission. The trading window for dealing in the company's shares has been closed until 48 hours after the announcement of the financial results.